Development Pre-Money
Cryo Medica
Oncology
Cryo Medica has developed a novel platform, needle and service model that can be seamlessly integrated into Doctor’s Offices, Surgical Centers and Hospitals with increased effectiveness and comfort for all stakeholders. Along with Prostate Cancer, Cryo Ablation is used to treat Kidney Tumors, Breast, Liver and Lung with reimbursement established.
Development Pre-Money
Cryo Medica
Oncology
Cryo Medica has developed a novel platform, needle and service model that can be seamlessly integrated into Doctor’s Offices, Surgical Centers and Hospitals with increased effectiveness and comfort for all stakeholders. Along with Prostate Cancer, Cryo Ablation is used to treat Kidney Tumors, Breast, Liver and Lung with reimbursement established.
Development Pre-Money
Cryo Medica
Oncology
Cryo Medica has developed a novel platform, needle and service model that can be seamlessly integrated into Doctor’s Offices, Surgical Centers and Hospitals with increased effectiveness and comfort for all stakeholders. Along with Prostate Cancer, Cryo Ablation is used to treat Kidney Tumors, Breast, Liver and Lung with reimbursement established.
The opportunity
Cancer ablation is not a new technique, with Boston Scientific dominating Prostate market after their acquisition of Galil Medical. A smaller more nimble system was needed to move the therapy out of the hospital to outpatient clinics and urology offices.
The solution
A portable Cryo Ablation system for the treatment of Prostate and other cancers. Moves treatment to the clinic and practice Significant revenue opportunity for Urologists under current approved reimbursement codes . Portable vs cart based, enabling HASS model.
The opportunity
Cancer ablation is not a new technique, with Boston Scientific dominating Prostate market after their acquisition of Galil Medical. A smaller more nimble system was needed to move the therapy out of the hospital to outpatient clinics and urology offices.
The solution
A portable Cryo Ablation system for the treatment of Prostate and other cancers. Moves treatment to the clinic and practice Significant revenue opportunity for Urologists under current approved reimbursement codes . Portable vs cart based, enabling HASS model.
The opportunity
Cancer ablation is not a new technique, with Boston Scientific dominating Prostate market after their acquisition of Galil Medical. A smaller more nimble system was needed to move the therapy out of the hospital to outpatient clinics and urology offices.
The solution
A portable Cryo Ablation system for the treatment of Prostate and other cancers. Moves treatment to the clinic and practice Significant revenue opportunity for Urologists under current approved reimbursement codes . Portable vs cart based, enabling HASS model.
350+
men die yearly due to prostate cancer
60%
of newly diagnosed men are candidates for targeted therapy
70 - 90%
survival rate without any biochemical treatment
350+
men die yearly due to prostate cancer
60%
of newly diagnosed men are candidates for targeted therapy
70 - 90%
survival rate without any biochemical treatment
350+
men die yearly due to prostate cancer
60%
of newly diagnosed men are candidates for targeted therapy
70 - 90%
survival rate without any biochemical treatment
ARTICLES
Press
Bringing Hospital-Level Care to Rural America
Feb 25, 2025
Brooklyn-based 10XBeta is developing a modular mobile healthcare platform...
Press
10XBeta Selected by ARPA-H's PARADIGM Program to Transform Rural Healthcare
Feb 19, 2025
10XBeta will lead the development of an integrated, scalable mobile platform designed to bring cutting-edge healthcare services to underserved rural communities
Press
Validose Secures $2M in Pre-Seed Funding to Solve Clinical Trial Medication Adherence
Feb 18, 2025
The platform is the first to combat non-adherence in clinical trials, a cause of 30% of failures...
Press
Bringing Hospital-Level Care to Rural America
Feb 25, 2025
Brooklyn-based 10XBeta is developing a modular mobile healthcare platform...
Press
10XBeta Selected by ARPA-H's PARADIGM Program to Transform Rural Healthcare
Feb 19, 2025
10XBeta will lead the development of an integrated, scalable mobile platform designed to bring cutting-edge healthcare services to underserved rural communities
Press
Validose Secures $2M in Pre-Seed Funding to Solve Clinical Trial Medication Adherence
Feb 18, 2025
The platform is the first to combat non-adherence in clinical trials, a cause of 30% of failures...
Press
Bringing Hospital-Level Care to Rural America
Feb 25, 2025
Brooklyn-based 10XBeta is developing a modular mobile healthcare platform...
Press
10XBeta Selected by ARPA-H's PARADIGM Program to Transform Rural Healthcare
Feb 19, 2025
10XBeta will lead the development of an integrated, scalable mobile platform designed to bring cutting-edge healthcare services to underserved rural communities
